Serum 25OH vitamin D3 level was 20 ng/ml.

Serum levels of calcitonin, α-fetoprotein and carcinoembryonic antigene (CEA) were within normal ranges. Serum concentration of parathyroid hormone-related peptide was not available to us. Treatment started with normal saline, furosemide and calcitonin. Despite aggressive hydration and continuous intake of furosemide and calcitonin, the patient’s condition gradually deteriorated during the next 48 hours with Inhibitors,research,lifescience,medical aggravation of hypercalcemia and deterioration of mental status. Therefore, 90 mg Pamidronate, which resulted in gradual decrement of serum ZD1839 order calcium level, was prescribed. Ultrasonographic evaluation of the abdomen revealed a 150 mm lobulated mass in the upper part of abdomen which

was confirmed by CT scan (figure 1). The patient underwent surgery, during which a large, lobulated, hard, hypervascular and irregular mass occupying the body and tail of the pancreas was observed. The mass could not be totally excised Inhibitors,research,lifescience,medical because of hypervascularity and severe bleeding potentials. Histopathologic Inhibitors,research,lifescience,medical evaluation revealed that the mass was a neuroendocrine tumor. Immunohistochemistry (IHC) staining, done in Iran, was positive for synaptophysin, alpha 1 antitrypsin and vimentin. Re-evaluation of IHC, done at the Department of Pathology, St. Michael Hospital, Toronto, Ontario, Canada, disclosed cytoplasmic immunopositivity for PTHrP (figure 2), somatostatin, calcitonin, serotonin and chromogranin. Ki-67 nuclear labeling

index Inhibitors,research,lifescience,medical was estimated at 1-3%. Figure 1 Abdominal computed tomography scan showing the pancreatic tumor Figure 2 Immunohistochemical staining showing positivity for parathyroid hormone related protein. After one week, because of paresthesia and serum calcium concentration of 7.1 mg/dl, calcium carbonate and calcitriol were prescribed Inhibitors,research,lifescience,medical followed by chemotherapy with Etoposide and VP16. After six months the patient underwent surgery for a second time in another hospital. This surgery was also unsuccessful at complete removal of the pancreatic mass. The neonate was also operated on by a team of pediatric surgeons; however, unfortunately she expired the day after the surgery. Discussion Present case is unique because of the large invasive tumor spanning whole length of pregnancy, severe post partum hypercalcemia, and birth of a baby with above-mentioned Rolziracetam malformations secondary to a pancreatic NET. Neuroendocrine tumors are rare neoplasms. The annual incidence is 2-3/100,000 and 30-50% of the tumors are functional.4,7 Pancreatic NET presenting with hypercalcemia secondary to PTHrP production constitute a small minority of these tumors. Because of the similarity of the clinical picture with multiple endocrine neoplasia type 1 (MEN1), the pathogenesis of hypercalcemia in patients with pancreatic NET was a real challenge.